Fusidic Acid
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Fusidic Acid: From Staphylococcal Infections to Exposure Keratitis
One-Sentence Summary
Fusidic acid is a steroidal bactericidal antibiotic with potent anti-staphylococcal activity, approved in several European countries as an ophthalmic gel (Fucithalmic® 1%) for bacterial conjunctivitis and widely used for staphylococcal skin and soft tissue infections. The TxGNN model predicts it may be effective for Exposure Keratitis, though only 1 tangentially related publication currently supports this specific direction. Among the 10 evaluated predictions, Post-Bacterial Disorder (ABSSSI) at rank 5 carries a completed Phase 3 RCT (NCT02570490, n=716) and warrants priority attention as a separate evaluation.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No Singapore registration on record |
| Predicted New Indication | Exposure Keratitis |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L4 |
| Singapore Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, no formal mechanism of action data is available in the regulatory database. Based on published pharmacology, fusidic acid is a steroidal antibiotic that irreversibly binds to the bacterial elongation factor G (EF-G)–GDP complex during ribosomal translocation, blocking peptide chain elongation and thereby inhibiting bacterial protein synthesis. It displays potent bactericidal or bacteriostatic activity against Staphylococcus aureus — including methicillin-resistant strains (MRSA and MRSE) — with MIC₉₀ values typically below 0.5 μg/mL, making it one of the more reliable topical anti-staphylococcal agents available.
The mechanistic bridge to exposure keratitis rests on fusidic acid's established ophthalmic precedent: Fucithalmic® 1% gel has received regulatory approval in multiple European countries (including the UK, Denmark, and Sweden) for the topical treatment of bacterial conjunctivitis. This confirms both ocular surface tolerability and clinically meaningful local anti-staphylococcal activity, and provides a pharmacological foundation for extrapolating to adjacent conditions of the corneal surface.
Exposure keratitis results from incomplete eyelid closure — due to facial palsy, proptosis, or post-surgical lagophthalmos — leaving the corneal epithelium chronically exposed to desiccation and secondary bacterial superinfection, most frequently caused by S. aureus. Topical fusidic acid could theoretically prevent or treat these secondary staphylococcal infections in an already-compromised cornea. However, no clinical trials have investigated this application, and the single available publication is only tangentially relevant, keeping the evidence firmly at the preclinical/mechanistic stage (L4).
Clinical Trial Evidence
Currently no related clinical trials registered for exposure keratitis.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 31246677 | 2019 | Case Series | Cornea | Largest reported case series of Tsukamurella spp.–associated ophthalmic infections, including corneal and conjunctival presentations; highlights the clinical spectrum of opportunistic ocular bacterial infections and the importance of targeted anti-staphylococcal/anti-bacterial selection in refractory periocular cases |
Singapore Market Information
Fusidic acid is not currently registered or marketed in Singapore, and no product licenses are on file. For international context, Fucithalmic® 1% ophthalmic gel (fusidic acid) is registered in several European jurisdictions for bacterial conjunctivitis, and oral/topical fusidic acid preparations (e.g., Fucidin®) are approved for staphylococcal skin and soft tissue infections across Europe and Asia-Pacific.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic rationale is coherent — European approval for bacterial conjunctivitis demonstrates ocular tolerability and anti-staphylococcal efficacy at the corneal surface — but no controlled clinical data exist specifically for exposure keratitis (L4 evidence, 0 trials, 1 tangentially related case series). Committing resources to this indication without any interventional pilot data is premature.
⚠️ Higher-Priority Finding: Among all 10 evaluated predictions, Post-Bacterial Disorder / Acute Bacterial Skin and Skin Structure Infections (rank 5) is supported by a completed Phase 3 double-blind multi-centre RCT (NCT02570490, n=716, oral sodium fusidate vs. oral linezolid), qualifying for L1 evidence and a "Proceed with Guardrails" recommendation. This indication should be prioritised for a dedicated repurposing evaluation report.
To advance exposure keratitis from Hold to active research, the following is needed:
- Retrospective case review or prospective pilot study of topical fusidic acid in exposure keratitis patients with documented staphylococcal superinfection
- Head-to-head comparison with current standard-of-care topical antibiotics (e.g., chloramphenicol, ciprofloxacin, tobramycin)
- Full safety review: obtain complete package insert including warnings, contraindications, and drug interaction data (currently unavailable in the data pack)
- Confirm ocular pharmacokinetics: tear film concentration, corneal penetration, and dosing frequency for Fucithalmic® formulation applied to an exposed cornea
- Singapore regulatory pathway assessment for a new ophthalmic indication, given the drug is currently not marketed locally
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.